Fig. 3.

In vivo efficacy of combined NIR-PIT targeting hEGFR and CD25. (a) Treatment schedule. (b) The fluorescence of the tumor decreased immediately after light exposure. White arrowheads represent the locations of tumors. A.U., arbitrary unit. (c) Tumor volume curves (n = 10; repeated measures two-way ANOVA followed by Tukey's test; ****, p < 0.0001). (d) Survival curves (n = 10; log-rank test with Bonferroni correction; *, p < 0.05, **, p < 0.01, ***, p < 0.001). The CD25-PIT and the combined PIT cleared the tumor in 1/10, 3/10 mice, respectively.